This thesis shows the role of GM-CSF signaling in tumor immunotherapy and the development of genetically modified, GM-CSF secreting, cell-based immunotherapies from several murine models to pilot Phase I clinical trial. Novel strategies to allow clinically relevant immunization schemes are detail with emphasis on encapsulation cell technology, a delivery methods that allows the local release of stable, standarized cytokine such as GM-CSF.